Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland

BACKGROUND: Abiraterone acetate (ABI) and Enzalutamide (ENZA) are second-generation hormone drugs that show breakthrough activity in post-chemotherapy, metastatic castration-resistant prostate cancer (mCRPC). The leading oncological and urological guidelines indicate both drugs with the same strong...

Descripción completa

Detalles Bibliográficos
Autores principales: Sigorski, Dawid, Wilk, Michał, Gawlik-Urban, Angelika, Sałek-Zań, Agata, Kiszka, Joanna, Malik, Mateusz, Czerko, Katarzyna, Kuć, Kamil, Szczylik, Cezary, Kubiatowski, Tomasz, Cybulska-Stopa, Bożena, Filipczyk-Cisarż, Emilia, Bodnar, Lubomir, Skoneczna, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108911/
https://www.ncbi.nlm.nih.gov/pubmed/37077831
http://dx.doi.org/10.3389/fonc.2023.1108937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108911/
https://www.ncbi.nlm.nih.gov/pubmed/37077831
http://dx.doi.org/10.3389/fonc.2023.1108937

Ejemplares similares